Advanced Enzyme Technologies Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts less than Nifty Microcap 250 and 3.4 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Advanced Enzyme Technologies' board approved audited consolidated and standalone financial results for FY25 (year ended March 31, 2025) along with Q4 results. Consolidated revenue from operations rose about 2.1% year-on-year to Rs. 6,369.10 million from Rs. 6,238.68 million, while consolidated net profit dipped slightly to Rs. 1,339.74 million from Rs. 1,369.51 million. On the standalone side, revenue fell about 3.8% to Rs. 3,514.11 million and net profit declined to Rs. 1,024.20 million from Rs. 1,081.23 million. The board declared an interim dividend of Rs. 4 per share (200% on Rs. 2 face value) for FY26 with a record date of May 17, 2025, and recommended a final dividend of Rs. 1.20 per share (60%) for FY25, subject to shareholder approval at the AGM on July 30, 2025. Statutory auditors MSKA & Associates issued an unmodified (clean) opinion. The board also approved incorporating a new wholly-owned subsidiary in India and appointed a new secretarial auditor for five years.
A clean audit report and steady dividend payouts (Rs. 5.20 per share total) reflect financial stability and reward shareholders well, but the modest revenue growth and slight dip in profits signal a flat-to-soft year, which may limit near-term stock price excitement though it remains attractive for income-focused investors.